Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
The stock's rise snapped a four-day losing streak.
Updated figures from the WHO show that more than one in five adults aged between 15 and 49 globally have the infection.
CPI data matched expectations; Goods inflation rose to its highest level since May 2023. Albertson’s terminates merger with ...
Wall Street trading got off to a mixed start on Wednesday as investors digested last month's all-important CPI reading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback